Northwest Biotherapeutics (NWBO) Will Delist from Nasdaq Will Begin Trading OTC

Go back to Northwest Biotherapeutics (NWBO) Will Delist from Nasdaq Will Begin Trading OTC

NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

December 7, 2016 8:00 PM EST

BETHESDA, Md., Dec. 7, 2016 /PRNewswire/ -- Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company's plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw the Company's common stock from listing on Nasdaq.  Upon withdrawal from Nasdaq, the Company plans to begin trading on the over-the-counter (OTC) market.... More